Patient-specific tumor neoantigens and shared tumor-associated antigens

Class

Personalized multi-epitope peptide cancer vaccine

Pathway

Primes CD8+ cytotoxic and CD4+ Th1 T-cell anti-tumor immunity; administered alongside chemotherapy and pembrolizumab (PD-1 blockade)

Notes

original target text: Patient-specific tumor neoantigens and shared tumor-associated antigens (e.g. NY-ESO-1, SOX2, p53), HLA class I/II-presented

This mechanism targets tumor neoantigens and tumor-associated antigens rather than a single receptor or enzyme. Neoantigens arise from mutations unique to an individual's cancer and are not present on normal cells, while tumor-associated antigens (such as NY-ESO-1, SOX2, or p53) are proteins overexpressed or aberrantly expressed by tumors but also found, at lower levels, in some normal tissues. A personalized multi-epitope vaccine selects peptide fragments derived from these antigens, matched to the patient's own HLA (human leukocyte antigen) class I and II molecules, which are the cell-surface proteins responsible for displaying protein fragments to the immune system. By delivering multiple such peptides, the vaccine aims to prime both CD8+ cytotoxic T cells, which directly kill antigen-bearing tumor cells, and CD4+ helper T cells, which support and sustain that cytotoxic response. This approach is relevant across solid tumors with sufficient mutational burden to generate distinct neoantigens, and is often paired with chemotherapy, which can release tumor antigens and transiently reshape the immune environment, and with checkpoint blockade targeting PD-1, which removes a brake on T-cell activity so that vaccine-primed T cells can act more effectively against tumor cells.